An interventional study of HistoSonics Edison® System and Chemotherapy in Colorectal Cancer, Liver Metastases and Liver Cancer, sponsored by Case Comprehensive Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Case Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center — 3 open to participants now, 4 under way, none of them phase 3. Colorectal Neoplasms · Case Comprehensive Cancer Center.
Among the 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center, this one is the only one that started in 2025, is one of 4 with no phase, and was the 16th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 18+
Case Comprehensive Cancer Center · Sites in United States
Ages 18+
Case Comprehensive Cancer Center · Sites in United States
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3
First in 1996; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 17 across the 9 interventional studies, 72 across the 8 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Case Comprehensive Cancer Center is the lead sponsor of 496 studies on the registry; 61 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.
2 of the studies in Colorectal Neoplasms by Case Comprehensive Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044362Case Comprehensive Cancer CenterHistotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | 2026-12-01 |
| NCT07219745Case Comprehensive Cancer CenterTransanal Irrigation for the Management of Early Low Anterior Resection Syndrome (LARS) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM). The main question this clinical trial aims to answer is:
Participants will:
This is a prospective trial testing the benefits of histotripsy plus chemotherapy for participants with colorectal liver metastasis. Histotripsy has been approved by the FDA with De Novo classification for non-invasive destruction of liver tumors. Up to 100 participants with colorectal cancer liver metastasis will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants will undergo combined treatment with Histotripsy and chemotherapy without interruption in the chemotherapy.
Device: HistoSonics Edison® System · Drug: Chemotherapy
Histotripsy is a novel, totally non-invasive, non-ionizing, and non-thermal ablation technique that mechanically disrupts tumors through precisely controlled acoustic cavitation. Histotripsy is administered via HistoSonics Edison® System.
Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).
Radiologic tumor viability
As assessed by the degree of short-term local tumor control in Colorectal Liver Metastasis(CRLM)
Time frame: 90 days post-treatment
Rate of Tumor Necrosis
Biopsy results will be used to assess the degree of tumor necrosis in treated lesions.
Time frame: 30 days post-treatment
Percentage of Viable Tumor in Lesion
Biopsy results will be used to assess the percentage of lesions that have viable tumor.
Time frame: 30 days post-treatment
Infiltration of CD4
Biopsy results will be used to assess the infiltration of CD4.
Time frame: 30 days post-treatment
Infiltration of CD8
Biopsy results will be used to assess the infiltration of CD8.
Time frame: Baseline, 30 days post-treatment
Infiltration of B-cells
Biopsy results will be used to assess the infiltration of B-cells.
Time frame: 30 days post- treatment
Infiltration of CD45
Biopsy results will be used to assess the infiltration of CD45.
Time frame: 30 days post-treatment
Infiltration of CD68
Biopsy results will be used to assess the infiltration of CD68.
Time frame: 30 days post-treatment
Infiltration of PD-1
Biopsy results will be used to assess the infiltration of PD-1.
Time frame: 30 days post-treatment
Infiltration of PD-L1
Biopsy results will be used to assess the infiltration of PD-L1.
Time frame: 30 days after treatment
Infiltration of CTLA-4
Biopsy results will be used to assess the infiltration of CTLA-4.
Time frame: 30 days post-treatment
Overall Survival
Median overall survival will be measured up to 2 years post treatment.
Time frame: Up to 24 months post-treatment
Progression Free Survival (PFS)
The rate of progression free survival will be measured up to 2 years post treatment.
Time frame: Up to 24 months post-treatment
30 day Complications
The safety profile of the treatment, as measured by the complications at 30 days.
Time frame: 30 days post-treatment
90 day Complications
The safety profile of the treatment, as measured by the complications at 90 days.
Time frame: 90 days post-treatment
Plan to share: No — There is no need for sharing IPD for this clinical trial.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 12 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Case Comprehensive Cancer Center →